CN115364126A

CN115364126A - Application of lactobacillus reuteri in preparation of medicine for treating polycystic ovarian syndrome

Info

Publication number: CN115364126A
Application number: CN202110534687.7A
Authority: CN
Inventors: 杜艳芝; 李尚�; 翟君钰; 陈子江
Original assignee: Renji Hospital Shanghai Jiaotong University School of Medicine
Current assignee: Renji Hospital Shanghai Jiaotong University School of Medicine
Priority date: 2021-05-17
Filing date: 2021-05-17
Publication date: 2022-11-22
Anticipated expiration: 2041-05-17
Also published as: CN115364126B

Abstract

The invention relates to the field of biomedicine, in particular to application of lactobacillus reuteri in preparing a medicine for treating polycystic ovarian syndrome, wherein the polycystic ovarian syndrome is induced by organism biological clock disorder. The invention defines the important roles of the interaction network of key intestinal flora, fecal metabolites and serum metabolites in the polycystic ovarian syndrome induced by the body biological clock disorder and the treatment effect of lactobacillus reuteri on the polycystic ovarian syndrome induced by the body biological clock disorder through in vivo animal experiments and multigroup sequencing combined analysis.

Description

Application of lactobacillus reuteri in preparation of medicine for treating polycystic ovarian syndrome

Technical Field

The invention relates to the field of biomedicine, in particular to application of a probiotic lactobacillus reuteri in improving the treatment of organism biological clock disorder and polycystic ovary syndrome.

Background

Polycystic ovary syndrome (PCOS) is a common endocrine metabolic disease of women in the childbearing age, the incidence rate is about 7% -10%, the endocrine disorder syndrome is characterized by rare ovulation or no ovulation, polycystic ovary, concomitant high androgen or insulin resistance and the like, meanwhile, the symptoms of obesity, infertility and the like are often accompanied, and long-term complications such as coronary heart disease, endometrial cancer and the like are increased.

PCOS is one of the more complex diseases of gynecological endocrine, the pathogenesis of the PCOS is still unclear, and the PCOS is always the focus of research and has important clinical significance. In recent years, large-scale Genome-Wide Association Studies (GWAS) have found a number of genetic genes that may play an important role in the development of PCOS. However, not all patients with genetic disease-causing gene mutations develop symptoms of PCOS, and thus the external environment plays an important role in the onset of PCOS. The existence of normal biological clock rhythm is closely related to the homeostasis of the environment in the body, so that the body can better cope with environmental changes. Previous studies have shown that biological clock disorders are closely related to abnormal glycolipid metabolism in the body, and therefore, the biological clock disorders are likely to be involved in the development of PCOS. The search for a method for improving the biological clock disorder also contributes to the clinical diagnosis and treatment of PCOS.

To date, there is no well-established optimal regimen for treating PCOS, and a relatively well-established drug therapy for patients with ovulation failure and even infertility in PCOS is assisted with pregnancy using clomiphene and gonadotropin therapy. Aiming at the metabolic disorder and complications caused by the metabolic disorder of the patient, the Chinese diagnosis and treatment guideline of PCOS in 2018 proposes that the intervention of life style, including diet management and proper exercise, is a preferred scheme for relieving the PCOS. In addition, according to the condition of a patient, oral contraceptive is taken to reduce the androgen level by using British 35, and metformin relieves the glucose metabolism disorder and the like in clinic.

In recent years, increasing research has suggested that gut flora may be associated with insulin resistance and hyperandrogenism of PCOS. The intestinal flora of PCOS patients was significantly altered compared to control women. Letrozole-induced PCOS-like mice and dehydroepiandrosterone-induced PCOS-like mice develop gut flora disturbances, elevated androgen levels, abnormal glycolipid metabolism, abnormal estrous cycles, and ovarian polycystic changes, among others. After the treatment of the lactobacillus and the fecal microorganism transplantation of healthy mice, the androgen synthesis in mice can be reduced, the glycolipid metabolic disturbance can be relieved, and the abnormal estrus cycle and the ovary form can be improved. Thus, probiotics such as lactobacillus may have a therapeutic effect on PCOS. At present, the 16s rDNA sequencing technology and the metagenome sequencing technology of bacteria have achieved breakthrough development in intestinal microecology research, and by analyzing the PCOS-related key flora structure, the molecular pathological mechanism of the bacteria can be helped to be known, and a new angle and theoretical basis are provided for clinical diagnosis and treatment.

In the treatment of PCOS, patients need to have certain autonomy to strictly control diet and strengthen exercise during life style intervention to achieve the goal of improving body metabolism. Although oral contraceptives can reduce androgen levels in patients with PCOS, they also result in a rapid increase in estrogen levels to some extent, and prolonged contraceptive use can have adverse effects on the body. The administration of hypoglycemic agents such as metformin, rosiglitazone, pioglitazone and the like may also cause side effects such as gastrointestinal reactions in patients. The intestinal flora treatment provides a new idea for the treatment of PCOS, but redundant single strain supplement may cause dysbacteriosis of organisms, but the general metabolism is influenced, and no research is provided at present to suggest the combined application of a group of intestinal flora in the treatment of PCOS. As the surgical treatment of patients with sterility due to PCOS, electro-cautery, multi-point puncture or laser perforation under a laparoscope and the like can cause irreversible damage to ovaries to a certain extent, so that the surgical treatment is rarely recommended in clinical work at present. In addition, in the ovulation-promoting process of a PCOS (human ovarian syndrome) patient assisted by In-vitro fertilization (IVF), due to the fact that a large number of follicles are recruited and high-density gonadotropin receptors, the PCOS patient is more sensitive to the response of the ovulation-promoting drug, most small follicles can develop and mature under the stimulation of the ovulation-promoting drug, ovarian hyperstimulation syndrome is very easy to occur, and ascites, hydrothorax and pericardial effusion, thromboembolism and multi-organ failure can be seen In severe patients, and even death can be caused. Therefore, a new method is developed, and the biomarker and the treatment method which have small wound, high sensitivity and good specificity are found to have important significance for the clinical diagnosis and treatment of PCOS.

Disclosure of Invention

The invention aims to provide application of probiotic lactobacillus reuteri in improving organism biological clock disorder and treating polycystic ovary syndrome.

In a first aspect of the invention, the application of lactobacillus reuteri in preparing a medicine for treating polycystic ovarian syndrome is provided.

Furthermore, the polycystic ovarian syndrome is induced by organism biological clock disorder.

Furthermore, the application is the application in preparing the medicine for improving liver lipid accumulation, serum lipid metabolism disorder, glucose metabolism disorder, hyperandrogenism, ovarian polycystic change or estrus cycle disorder induced by organism biological clock disorder.

Furthermore, the application is the application in preparing medicines for improving intestinal flora, fecal metabolites and serum metabolites which play a role in the polycystic ovary syndrome lipid metabolism disorder induced by organism chime disorder.

Furthermore, the disorder of the polycystic ovary syndrome dyslipidemia induced by the disorder of the biological clock of the body comprises the abnormality of serum triglyceride, free fatty acid, low density lipoprotein, cholesterol and high density lipoprotein.

Further, the intestinal flora includes Lactobacillus, ruminobacter-010, clostridium stenotrophyi-1, and g _ Family _ XIII _ AD3011_ group; the fecal metabolites include 13-methyltetradecanoic acid, nicotinic acid, glycyl, 9-carbonyl-trans, cis-conjugated linoleic acid, succinic acid, L-glutamine, azelaic acid, N-acetyl-L-glutamic acid, palmitic acid, cis-eicosenoic acid, MG (18/0; the serum metabolites include cortisol, cis-9-palmitoleic acid, capric acid, dUMP and 13-methyltetradecanoic acid.

In a second aspect of the invention, a medicament for treating polycystic ovary syndrome induced by organism biological clock disorder is provided, wherein the medicament takes lactobacillus reuteri as an active ingredient.

Furthermore, the medicine for treating polycystic ovarian syndrome induced by organism biological clock disorder is an oral preparation.

Further, the oral preparationThe dose of Lactobacillus reuteri in the preparation is 1 × 10 ⁹ －1× 10 ¹⁰ CFU/dose/day.

According to the research of the invention, the biological CLOCK disorder caused by continuous darkness can cause abnormal expression of liver core rhythm genes of rats, including BMAL1, CLOCK, PER1, PER2, NR1D1 and NR1D2, and PCOS symptoms such as hyperandrogenism, increased ratio of serum LH/FSH, abnormal glycolipid metabolism, estrus cycle disorder, ovarian polycystic change and the like are caused, so that the biological CLOCK disorder is closely related to the generation and development of PCOS. After the lactobacillus reuteri is treated, abnormal expression recovery of liver rhythm genes PER2 and NR1D1 of a dark rat approaches to normal control, meanwhile, the level of serum Sex hormone binding protein (SHBG), insulin resistance, estrus cycle disorder and ovarian polycystic change are improved, and the conditions of liver lipid accumulation and serum lipid metabolism disorder are obviously relieved.

The invention is clear that after the biological clock of the rat is disordered, <xnotran> -1 (g __ Corynebacterium _ 1), (g __ Atopostipes), (g __ Sporosarcina), (g __ Jeotgalicoccus), (g __ Mesorhizobium _ sp), _ RFN54 (g __ unidentified _ rumen _ bacterium _ RFN 54), (g __ Brachybacterium), (g __ Candidatus _ Brocadia), (g __ Oceanobacillus), (g __ Facklamia), (g __ Psychrobacter), g __ Family _ XIII _ AD3011_ group , -009 (g __ Ruminococcaceae _ UCG-009), -010 (g __ Ruminococcaceae _ UCG-010), (g __ Bacillus), g __ Faecalitalea , -003 (g __ Prevotellaceae _ UCG-003), (g __ Myroides), -1 (g __ Clostridium _ sensu _ stricto _ 1), -014 (g __ Ruminococcaceae _ UCG-014), (g __ Lactobacillus), g __ Elusimicrobium , (g __ Pasteurella), -1 (g __ Prevotella _ 1), (g __ Vagococcus), - (g __ Escherichia-Shigella), (g __ Globicatella) (g __ Butyricimonas) . </xnotran> <xnotran> , (g __ Lactobacillus), -010 (g __ Ruminococcaceae _ UCG-010), -1 (g __ Clostridium _ sensu _ stricto _ 1), -009 (g __ Ruminococcaceae _ UCG-009) g __ Family _ XIII _ AD3011_ group , PCOS . </xnotran>

The invention is clear that the content of a large amount of excrement metabolites is obviously changed after the biological clock of a rat is disordered. Wherein MG (18/0), ursodeoxycholic acid (Ursodeoxycholic acid), 9-carbonyl-trans, cis-conjugated linoleic acid (9-OxoODE), glycyl (Glycyl-valene), 3-Methyladenine (3-methylalandine), L-Carnitine (L-Carnitine), palmitic acid (Palmitic acid), chenodeoxycholic acid (Chenodeoxycholic acid), azelaic acid (Nonanedioic acid), 13-methyltetradecanoic acid (13-Methylmyristic acid), succinic acid (Succinic acid), N6-trimethyllysine (N6, N6-Trimethyl-L-lysine), myristic acid (Myristic acid), trigonelline (Trigonaline), nicotinic acid (Nicotinic acid), cis-eicosenoic acid (cis-Gondoic acid), creatinine (Creatine), pantothenic acid (Panthonic acid), ornithine (Ornithine), N-acetylaspartic acid (N-acetylaspartic acid), ferulic acid (Ferulic acid) murrocholic acid (Murocholic acid), oleic acid (Oleic acid), 16-Hydroxyhexadecanoic acid (16-Hydroxyhexadecanoic acid), adenine (Adenine), maleic acid (Maleic acid), pentadecanoic acid (Pentadecylic acid), gamma-Aminobutyric acid (gamma-Aminobutyric acid), 3-Methylxanthine (3-Methylxanthine), cAMP, L-Glutamine (L-Glutamine), 3-Indoleacetic acid (3-Indoleacetic acid) and N-Acetyl-L-glutamic acid (N-Acetyl-L-glutamic acid) play an important role in Lactobacillus reuteri in ameliorating biological clock disorders, and in ameliorating PCOS-like induced by biological clock disorders.

The invention is clear that the content of a large amount of serum metabolites is obviously changed after the biological clock of the rat is disordered. Among them, allantoin (alantoin), 13-methyltetradecanoic acid (13-Methylmyristic acid), thymine (Thymine), dehydroabietic acid (Dehydroabietic acid), gamma-Linolenic acid (gamma-Linolenic acid), tetradecanoic acid (Myristic acid), dUMP p, cortisol (Cortisol), cis-9-Palmitoleic acid (cis-9-Palmitoleic acid), capric acid (Capric acid) and Citrulline (Citrulline) play an important role in lactobacillus reuteri in ameliorating biological clock disorders and in ameliorating PCOS-like induced by biological clock disorders.

By bioinformatics joint analysis of multiomics, the present invention clearly demonstrates that alterations in lactobacillus, ruminobacter-010, clostridium-1 and g _ Family _ XIII _ AD3011_ group, which act together to cause alterations in the fecal metabolites 13-methyltetradecanoic acid, nicotinic acid, glycyl, 9-carbonyl-trans, cis-conjugated linoleic acid, succinic acid, L-glutamine, azelaic acid, N-acetyl-L-glutamic acid, palmitic acid, cis-eicosenoic acid, MG (18.

The present invention further defines that the serum contents of cortisol, cis-9-palmitoleic acid, capric acid, and 13-methyltetradecanoic acid in the sera of two groups of people are significantly different using serum samples from PCOS patients and control normal women, and that these metabolites are significantly different from Body Mass Index (BMI), triglycerides (TG), total Cholesterol (CHOL), high-density lipoprotein Cholesterol (HDL-C), anti-Mullerian Hormone (Anti-Mullerian Hormone, AMH), luteinizing Hormone (LH), LH-FSH/FSH), testosterone (Testosterone, T, and ₀ ) Prolactin (PRL), thyroid Stimulating Hormone (TSH) and high embryo rates are clearly related. In addition, the invention provides a screening method of a metabolic marker for PCOS, which is based on LC-MS technology to quantitatively detect the content of the metabolic marker in serum and a subject working characteristic curve (receiver operating characteristic curve,ROC) as a panel of diagnostic markers, cortisol, cis-9-palmitoleic acid, and 13-methyltetradecanoic acid as combined markers to aid in the diagnosis of PCOS. Meanwhile, the group of markers can also jointly use LH/FSH ratio, serum testosterone and serum triglyceride, so that the diagnostic sensitivity and specificity are improved, and the kit is used for clinical diagnosis of PCOS.

<xnotran> PCOS , , (g __ Chrysosporum), (g __ Fusobacterium), (g __ Podoviridae), (g __ Shigellap), (g __ Comamonas ), (g __ Parabacteroides), γ - (g __ Lambdalikevirus), (g __ Klebsiella), (g __ Escherichia), (g __ Tannerella), (g __ Siphoviridae) (g __ Barnesiella) . </xnotran> Furthermore, these gene sets were associated with T ₀ The intestinal microorganisms, AMH, LH, TSH, fasting blood glucose and BMI are obviously related, which indicates that the intestinal microorganisms may have certain functions in the generation and development process of PCOS and provides a new angle for the diagnosis and treatment of PCOS.

The invention has the advantages that:

the invention utilizes continuous dark treatment to construct a PCOS-like rat disease model induced by biological clock disorder and a treatment model of treating a dark rat by lactobacillus reuteri, and takes excrement and peripheral serum to carry out experiments such as excrement 16s-rDNA sequencing, excrement UHPLC-TOF-LC-MS, serum UHPLC-TOF-LC-MS and the like. Through in vivo animal experiments and multigroup sequencing combined analysis, the important roles of the interaction network of the key intestinal flora, the fecal metabolites and the serum metabolites in the PCOS phenotype induced by the biological clock disorder and the treatment effect of the lactobacillus reuteri on the model are determined.

Drawings

FIG. 1: lactobacillus reuteri improves PCOS-like phenotypes induced by biological clock disorders.

A. A molding method. We randomly divided 24 SPF-grade SD rats (6 weeks old, about 160 grams) into 3 groups of 8 rats each. Control group: normal light treatment for 8 weeks, dark group: dark treatment was continued for 8 weeks, dark + lactobacillus group: the lactobacillus reuteri was administered intragastrically while the treatment was continued for 8 weeks in darkness. B. Body weight of rats in control, dark and dark + lactobacillus groups weekly during 8 weeks of molding. C. Oil red staining of rat livers of control, dark and dark + lactobacillus groups. D. Transmission electron microscopy of rat livers of control group, dark group and dark + lactobacillus group. E. Lipid detection in rat livers of control, dark and dark + lactobacillus groups. F. Lipid assay in rat serum of control group, dark group and dark + lactobacillus group. G. Results of Oral Glucose Tolerance Test (OGTT) of rats in a control group, a dark + light recovery 1 week group, a dark + light recovery 2 week group, a dark + xylo-oligosaccharide group, a dark + lactobacillus group and a dark + melatonin group. Left panel blood glucose levels for each group, right panel Area Under the Curve (AUC) for each group. H. Ovarian HE staining of rats in control, dark and dark + lactobacillus groups. I. Estrus cycles of rats in control, dark and dark + lactobacillus groups. J. The ratio of LH/FSH levels, testosterone levels and SHBG levels in the serum of rats in the control group, the dark group and the dark + Lactobacillus group.

We find that the biological clock disorder caused by continuous darkness can cause abnormal expression of liver core rhythm genes of rats and PCOS-like symptoms such as androgen rise, glycolipid metabolism disorder, estrus cycle disorder, ovarian polycystic change and the like. While we administered lactobacillus reuteri intragastric (fig. 1A) to rats while treating the rats for 8 weeks in the dark, we found that although the body weight of each group of rats was not changed (fig. 1B), lactobacillus reuteri could significantly improve liver lipid accumulation in dark rats (fig. 1c, d), lower triglyceride and low density lipoprotein levels in the liver of dark rats, and raise lower cholesterol and high density lipoprotein levels in the liver (fig. 1E); lactobacillus reuteri also significantly increased lower cholesterol and high density lipoprotein levels in the sera of dark rats (fig. 1F). Meanwhile, lactobacillus reuteri improved the glucose tolerance level in dark rats (fig. 1G). In addition, irregular cystic follicle increases in the ovary of dark rats, decreasing the number of corpus luteum, while irregular cystic follicle decreases in the ovary of dark + lactobacillus treated rats, increasing the number of corpus luteum (fig. 1H), indicating that lactobacillus reuteri improved the persistent dark-induced cystic change in the ovary of PCOS-like rats. Similarly, lactobacillus reuteri also improved the disturbed estrus cycle in dark rats to some extent in the estrus cycle (fig. 1I). Furthermore, lactobacillus reuteri significantly alleviated the higher SHBG levels in the serum of dark rats, but only tended to improve the serum LH/FSH ratio and testosterone levels (fig. 1J).

FIG. 2: total principal component differential analysis of fecal and serum metabolites. A. Positive ion mode of the fecal metabolites PCA (Principal Component Analysis), PLS-DA (Partial Least Square constituent Analysis) and OPLS-DA (ortho genomic PLS-DA). B. Fecal metabolites of negative ion mode PCA, PLS-DA and OPLS-DA. C. Serum metabolites of positive ion mode, PCA, PLS-DA and OPLS-DA. D. The serum metabolites PCA, PLS-DA and OPLS-DA in negative ion mode.

After 8 weeks of modeling, feces and fasting serum of rats in the control group, the dark group and the dark + lactobacillus group were collected and subjected to UHPLC-TOF-LC-MS sequencing, respectively. By PCA, PLS-DA and OPLS-DA analysis, we can see significant differences in fecal and serum metabolites in the control, dark and dark + Lactobacillus rats (FIG. 2).

FIG. 3: intestinal flora (genus), fecal metabolites and serum metabolites that play an important role in the improved PCOS-like phenotype of lactobacillus reuteri.

A. Differential intestinal flora (genus) between control, dark and dark + lactobacillus groups. B. Differential serum metabolites between control, dark and dark + lactobacillus groups. C. Differential fecal metabolites between control, dark and dark + lactobacillus groups. Simultaneously, 3 screening conditions are met: (1) the dark group vs. the control group P is less than 0.05, (2) the dark + lactobacillus group vs. the dark group P is less than 0.05, and (3) the dark + lactobacillus group vs. the control group P is more than or equal to 0.05.

The feces of rats in a control group, a dark group and a dark plus lactobacillus group are used for 16s-rDNA sequencing, and simultaneously, the UHPLC-TOF-LC-MS sequencing result of the feces and serum of the rats is used for screening intestinal flora, feces metabolites and serum metabolites which possibly play an important role in improving PCOS phenotype of the lactobacillus reuteri. 3 conditions are satisfied during screening: (1) the dark group vs. the control group P is less than 0.05, (2) the dark + lactobacillus group vs. the dark group P is less than 0.05, and (3) the dark + lactobacillus group vs. the control group P is more than or equal to 0.05.

As a result, it was found that intestinal flora (genera) that may play an important role in improving biological clockwork and improving PCOS-like phenotypes induced by biological clockwork were improved by lactobacillus reuteri, including lactobacillus, ruminobacillus-009, ruminobacillus-010, clostridium strictum-1, and g _ Family _ XIII _ AD3011_ group (fig. 3A). In addition, important differential fecal metabolites include MG (18/0. Serum metabolites that may play a role in this include allantoin, 13-methyltetradecanoic acid, thymine, dehydroabietic acid, gamma-linolenic acid, tetradecanoic acid, dUMP p, cortisol, cis-9-palmitoleic acid, decanoic acid, and citrulline (fig. 3C).

FIG. 4 is a schematic view of: differential intestinal flora, fecal metabolites, and serum metabolites expression profiles. A. Relative abundance heatmap of differential intestinal flora. B. Differential fecal metabolite expression profiles. C. Differential serum metabolite expression profiles.

According to the 16s-rDNA sequencing results of rats in a control group, a dark group and a dark + lactobacillus group, the UHPLC-TOF-LC-MS sequencing results of excrement and serum and related full-spectrum identification analysis, a relative abundance heat map (4A) of differential intestinal flora (genus), an expression quantity heat map (4B) of differential excrement metabolites and an expression quantity heat map (4C) of differential serum metabolites are drawn, and the conditions of the differential flora and the differential metabolites in samples of the control group, the dark group and the dark + lactobacillus group are observed more intuitively through clustering.

FIG. 5: the multi-group combined analysis finds the intestinal flora (genus), fecal metabolites and serum metabolites that play a role in the improvement of PCOS-like serum lipid metabolism disorder by Lactobacillus reuteri. A. Using the correlations among all intestinal flora (genus), fecal metabolites, and serum metabolites, circos-plot analysis was performed for each group against control group, dark group, and dark + lactobacillus group, respectively. Screening conditions for Spearman correlation: r is more than 0.8, and P is less than 0.05. The red line represents positive correlation and the blue line represents negative correlation. B. All intestinal flora (genus), fecal metabolites and serum metabolites of the control group, the dark group and the dark + lactobacillus group were used for pruque Analysis (Procrustes Analysis) between intestinal flora (genus) and fecal metabolites (left), between fecal metabolites and serum metabolites (middle) and between intestinal flora (genus) and serum metabolites (right), respectively. C. Heat map of Spearman correlation between differential stool metabolites and serum indices. D. Heatmap of Spearman correlation between differential serum metabolites and serum indices. E. Heat map of Spearman correlation between differential intestinal flora (genus) and differential serum metabolites. F. Heatmap of Spearman correlation between differential intestinal flora (genus) and differential stool metabolites. G. Heat map of Spearman correlation between differential stool metabolites and differential serum metabolites. * P <0.05, P < 0.01, P < 0.001.H. Network interaction maps between gut flora (genus), fecal metabolites and serum metabolites that play a role in the improvement of PCOS-like serum lipid metabolism disorders by lactobacillus reuteri. P is less than 0.05.I. Schematic representation of Spearman correlation between targeted intestinal flora (genus), fecal metabolites and serum metabolites. P is less than 0.05. The red line represents positive correlation and the blue line represents negative correlation.

By utilizing 16s-rDNA sequencing and UHPLC-TOF-LC-MS sequencing results of excrement and serum, spearman correlation analysis is carried out on all intestinal flora (genus), excrement metabolites and serum metabolites, and found that the positive correlation is 948 and the negative correlation is 1266 in rats in a control group; the positive correlation in the dark group of rats was 988, and the negative correlation was 1079; and 851 positive correlations and 1102 negative correlations in the dark + lactobacillus group (fig. 5A), illustrating the differences between rat flora, fecal metabolites and serum metabolites in the different treatment groups. Furthermore, the probuk analysis also suggested that there was a strong correlation between the flora species abundance composition and the fecal metabolite abundance composition, and between the fecal metabolite abundance composition and the serum metabolite abundance composition, for each sample (fig. 5B). In order to explore the intestinal flora (genus), fecal metabolites and serum metabolites that may play a role in the improvement of PCOS-like serum lipid metabolism disorder by lactobacillus reuteri, we therefore correlated the above-mentioned differential fecal metabolites and differential serum metabolites with serum indicators including triglycerides, low density lipoproteins, cholesterol, high density lipoproteins, free fatty acids, glutamic-oxaloacetic transaminase, glutamic-pyruvic transaminase, C-reactive protein (fig. 5C, d), and also correlated the above-mentioned differential intestinal flora (genus), differential fecal metabolites and differential serum metabolites with each other (fig. 5E-G). We found that alterations in lactobacillus, ruminococcus-010, clostridium-1 and g _ Family _ XIII _ AD3011_ group, acting together, cause alterations in the fecal metabolites 13-methyltetradecanoic acid, nicotinic acid, glycyl, 9-carbonyl-trans, cis-conjugated linoleic acid, succinic acid, L-glutamine, azelaic acid, N-acetyl-L-glutamic acid, palmitic acid, cis-eicosenoic acid, MG (18/0.

FIG. 6: the content change of the target serum metabolite in the serum of the PCOS female and the diagnostic significance. Serum 13-methyltetradecanoic acid content in PCOS women and control women. Serum content of cis-9-palmitoleic acid in PCOS female and control female. Serum cortisol content in pcos women and control women. Serum capric acid content of PCOS female and control female. The relevance of 13-methyltetradecanoic acid, cis-9-palmitoleic acid, cortisol, capric acid to clinical indices.* P <0.05, P < 0.01, P < 0.001.F. The ROC curve for a single serum metabolite (cortisol, cis-9-palmitoleic acid, and 13-methyltetradecanoic acid), and for a combination of three metabolites (cortisol, cis-9-palmitoleic acid, and 13-methyltetradecanoic acid). ROC curve for LH/FSH ratio, ROC curve for the combination of three metabolites with LH/FSH ratio. BMI<ROC curve, BMI, combining three metabolites (cortisol, cis-9-palmitoleic acid, and 13-methyltetradecanoic acid) in 24 populations<ROC curve of the LH/FSH ratio of the combination of the three metabolites in the 24 population. I.T ₀ Horizontal ROC curve, three metabolites in combination with T ₀ Horizontal ROC curve. ROC curve for TG, ROC curve for three metabolites in combination with TG. K. ROC curve of combined TG ratio of three metabolites in population with BMI more than or equal to 24.

According to the animal experiment results, serum samples of 99 PCOS patients and 101 control normal women are collected, and the contents of cortisol, cis-9-palmitoleic acid, capric acid and 13-methyltetradecanoic acid in the serum are quantitatively detected by using an LC-MS (liquid chromatography-mass spectrometry) technology. We found that serum concentrations of 13-methyltetradecanoic acid and cis-9-palmitoleic acid were significantly reduced in PCOS patients (fig. 6A-B), cortisol levels were significantly increased (fig. 6C), and decanoic acid levels were significantly reduced (fig. 6D) compared to control women. Further performing Spearman analysis on metabolite content and clinical indexes, and prompting cortisol, TG, CHOL, AMH, LH and T as a result ₀ The obvious positive correlation is presented; 13-methyltetradecanoic acid and TG, LH/FSH and T ₀ The strain shows obvious negative correlation and shows obvious positive correlation with excellent embryo rate; capric acid and BMI, TG, AMH, LH/FSH and T ₀ Has obvious negative correlation and obvious positive correlation with HDL-C; cis-9-palmitoleic acid and TG, LH/FSH, T ₀ PRL, TSH showed significant negative correlation (FIG. 6E). Since the trend of capric acid in PCOS serum is opposite to that of the PCOS-like animal model induced by previous biological clockwork disorder, we considered cortisol, cis-9-palmitoleic acid and 13-methyltetradecanoic acid as markers for specific clinical diagnosis of PCOS and biological clockwork disorder subjects.

To clarify the sensitivity and specificity of this set of combined markers of cortisol, cis-9-palmitoleic acid and 13-methyltetradecanoic acid, we proceeded withAnd judging the diagnosis effect of the metabolite by the AUC in one step. AUC-ROC of the individual serum metabolite 13-methyltetradecanoic acid of 0.69, 95% CI of 0.62-0.76; cortisol having an AUC-ROC of 0.68 and a 95% CI of 0.61-0.76; AUC-ROC of cis-9-palmitoleic acid of 0.65, 95% CI of 0.57-0.72; AUC-ROC of the three serum metabolites combined was calculated as 0.81, 95% CI as 0.75-0.87 using logistic regression analysis (FIG. 6F). The LH/FSH ratio in this cohort had an AUC-ROC of 0.84, 95% CI of 0.79-0.90, while the three metabolite combinations with the LH/FSH ratio were used together for PCOS diagnosis with AUC-ROC as high as 0.91, 95% CI of 0.87-0.95 (FIG. 6G). Notably, the AUC-ROC for the cortisol, cis-9-palmitoleic acid and 13-methyltetradecanoic acid combined metabolites was 0.84, 95% CI was 0.77-0.91, while the AUC-ROC for the three metabolite combined LH/FSH ratio was 0.94, 95% CI was 0.91-0.98 for people with BMI less than 24 (FIG. 6H). T is ₀ Levels in this cohort AUC-ROC of 0.92, 95% CI of 0.89-0.96, and three metabolites combined T ₀ Used together for PCOS diagnosis, the AUC-ROC was as high as 0.96, 95% CI was 0.94-0.98 (FIG. 6I). In addition to LH/FSH and T ₀ The AUC-ROC for PCOS diagnosis using 3 metabolite combinations TG was also as high as 0.91 (95% CI.

FIG. 7: intestinal microbial LDA analysis of PCOS patients. And (3) analyzing intestinal microorganisms LEfSe of PCOS patients and control patients. The statistical difference was defined as LDA (Linear diagnostic analysis) > 2. <xnotran> PCOS (g __ Chrysosporum), (g __ Fusobacterium), (g __ Podoviridae), (g __ Shigella), (g __ Comamonas ), (g __ Parabacteroides), γ - (g __ Lambdalikevirus), (g __ Escherichia) (g __ Siphoviridae) , (g __ Klebsiella), (g __ Tannerella), (g __ Barnesiella) . </xnotran> (FIG. 7).

FIG. 8: and (3) analyzing correlation of MGS and PCOS clinical indexes. Intestines screened by metagenomic analysisThe way bacteria are aggregated into a plurality of MGS, correlation analysis is carried out on the MGS and clinical indexes, and PCOS enriched MGS and T are found ₀ AMH, LH, BMI are in positive correlation, and MGS and T enriched in a control group ₀ AMH and TSH were negatively correlated, while they were positively correlated with fasting glucose (fig. 8).

Detailed Description

The following examples are provided to illustrate specific embodiments of the present invention.

Example (b):

1. experimental Material

1.1 Experimental rats

Experiments were performed with SPF grade Sprague Dawley (SD) female 6 week old rats.

1.2 Primary reagents and solutions

Lactobacillus reuteri (taiwan, inc.); tissue fixative, oil red staining solution, hematoxylin staining solution, differentiation solution, bluing solution, glycerol gelatin-sealed tablet, electron microscope fixative, eosin staining solution (Servicebio corporation); absolute ethanol, acetone, xylene (national chemical group, chemical agents, ltd.); 812 embedding agent (SPI); osmic acid (Ted Pella Inc); trigyceride Assay kit, free fat Acid Assay kit, cholesterol Assay kit (Abcam corporation); rat HDL-C ELISA kit, rat LDL-C ELISA kit (CUSABIO Co.); triton-X100 (Shanghai Producer); 10 XPBS (Shanghai Yazyme Biotechnology Co., ltd.); acetonitrile, methanol (Merck); formic acid (Shanghai Anpu scientific and technology Co., ltd.); ultrapure water (Mili-Q); 2-chlorophenylalanine (Shanghai Jier Biochemical Co., ltd.); cholesterol standard (Sigma-Aldrich); DNA extraction kit e.z.n.a. @ tool DNA kit (Omega Biotek corporation); gel recovery kit (Axygen corporation); NEBNext Ultra DNA Library Prep Kit for Illumina, truseqPEClusterKitv3-cBot-HS, truseqSBSKitv3-HS (Shanghai Sharp next Biotech Co., ltd.).

1.3 Main Experimental instruments and Equipment

High-speed low-temperature Centrifuge (Centrifuge 5810R), high-speed low-temperature Centrifuge (Centrifuge 5415R), metal heater, electrothermal forced air drying cabinet, 4 ℃ refrigerator, -20 ℃ refrigerator, -80 ℃ refrigerator, microplate reader, IBM computer (analytical software), electronic balance (1/1000), inverted microscope, fluorescence microscope, micro-mixer, sitting-type automatic electrothermal pressure steam sterilizer, illumina MiSeq System, glucometer, cryomicrotome, glass slide, ultra-thin microtome, diamond slicer, transmission electron microscope, 150 mesh Square film copper mesh, bioruptarPico, high-resolution mass spectrometer AB Sciex Qtrap 0+, high-resolution mass spectrometer AB SCIEX Triple TOF 6600+, high-performance liquid chromatograph UHXera PLC LC-30A, freeze concentration centrifugal dryer LNG-798, chromatographic column Waters UPLC HSS C8 column, chromatographic column ACITY UPLC HSS 3 column.

2. Experimental method

2.1 oil Red dyeing

(1) Frozen section fixation of fresh liver tissue: and (3) rewarming and drying the frozen slices, fixing in a fixing solution for 15 minutes, washing with tap water and drying in the air.

(2) Oil red dyeing: immersing the slices in oil red dye liquor for dyeing for 8-10 minutes (covering and protecting from light), and washing with distilled water;

(3) Background differentiation: slightly differentiated with 75% alcohol, and washed with distilled water.

(4) Hematoxylin staining: and (3) dyeing the slices in hematoxylin dyeing solution for 3-5 minutes, washing with tap water, differentiating the differentiation solution, washing with tap water, returning blue to the blue solution, and washing with running water.

(5) Sealing: and (5) sealing the glycerol gelatin sealing agent.

(6) Microscopic examination and image acquisition and analysis.

2.2 Transmission Electron microscopy

(1) Material drawing and fixing: determining the material-taking part of fresh liver tissue, minimizing mechanical injury such as traction, contusion and extrusion, sampling within 1-3 min, and sampling tissue with a thickness of 1mm ³ Size. Before material drawing, a culture dish filled with electron microscope stationary liquid can be prepared in advance, the small tissue blocks are taken off in vitro and immediately put into the culture dish, and a scalpel is used for cutting the small tissue blocks into 1mm in the stationary liquid of the culture dish ³ Small tissue blocks. And transferring the cut small tissue blocks into an EP tube filled with a new electron microscope fixing solution for continuous fixation, and carrying out fixed storage and transportation at 4 ℃.0.1M PBS PB (pH 7.4) was rinsed 3 times for 15 minutes each.

(2) Post-fixing: 1% osmic acid in 0.1M phosphate buffer PB (pH 7.4) was fixed in the dark at room temperature for 2 hours. 0.1M phosphate buffer PB (pH 7.4) was rinsed 3 times for 15 minutes each.

(3) Dehydrating at room temperature: the tissue is sequentially added with 30% -50% -70% -80% -95% -100% -100% alcohol to be dehydrated for 20 minutes each time, and 100% acetone is added twice for 15 minutes each time.

(4) And (3) infiltration embedding: acetone 812 embedding medium =1, 37 ℃,2-4 hours, acetone 812 embedding medium =1, 2, 37 ℃ overnight, pure 812 embedding medium 37 ℃,5-8 hours. The pure 812 embedding medium was poured into the embedding plate and the samples were inserted into the embedding plate and then oven left overnight at 37 ℃.

(5) Polymerization: the embedded plate was polymerized in an oven at 60 ℃ for 48 hours, and the resin block was taken out for use.

(6) Ultrathin slicing: the resin block is subjected to 60-80nm ultrathin section by an ultrathin slicer, and the sheet is fished by a 150-mesh diamond film copper net.

(7) Dyeing: dyeing the copper mesh in a 2% uranium acetate saturated alcohol solution for 8 minutes in a dark place; cleaning with 70% ethanol for 3 times; cleaning with ultrapure water for 3 times; 2.6 percent of lead citrate solution avoids carbon dioxide dyeing for 8 minutes; the ultrapure water was washed 3 times and the filter paper was slightly blotted dry. The copper mesh slices are placed in a copper mesh box and dried overnight at room temperature.

(8) Observing under a transmission electron microscope, and collecting and analyzing images.

2.3 quantitative determination of rat liver and serum triglycerides, free fatty acids, total Cholesterol

The procedures were carried out according to the specifications of triglyceridequantifraction Assay kit (Abcam Corp., cat # ab 65336), free Fatty Acid Assay kit (Abcam Corp., cat # ab 65341), HDL and LDL/VLDL Cholesterol-Assay (Abcam Corp., cat # ab 65390), respectively.

2.4 quantitative determination of high-density lipoprotein and low-density lipoprotein in rat liver and serum

The procedures were performed according to the Rat HDL-C ELISA kit (CUSABIO Co., ltd., product No. CSB-E14399 r) and the Rat HDL-C ELISA kit (CUSABIO Co., product No. CSB-E16561 r), respectively.

2.5 H & E staining

(1) Fixing: washing the rat organ tissue which is taken out freshly by PBS, quickly placing the rat organ tissue in 4% paraformaldehyde, and fixing the rat organ tissue at 4 ℃ overnight;

(2) Flushing for 6 hours by running water;

(3) Specimen dehydration: firstly, soaking a specimen in 75% ethanol overnight, then soaking in 85% ethanol for 2 hours, then respectively soaking in 95% ethanol twice, each soaking for one hour, taking out, then placing in 100% ethanol twice, each soaking for 1 hour, and finishing specimen dehydration;

(4) Xylene is transparent: placing the dehydrated specimen in xylene for 30 minutes and then in another xylene for 15-20 minutes (determined by the transparency of the tissue);

(5) Paraffin embedding: the organ tissues are soaked in liquid paraffin for 1 hour, then soaked in another liquid paraffin for 1 hour, and then paraffin embedding and marking are carried out;

(6) Paraffin section: correcting the paraffin block into a cuboid or a cube, placing the cuboid or the cube in a paraffin slicer for continuous slicing, wherein the thickness is 5 mu m, placing the sliced sheet in water at 42 ℃ for unfolding, pasting the paraffin slice on a glass slide after flattening, and then placing the glass slide on a baking sheet machine at 42 ℃ for overnight. Then storing the paraffin sections at normal temperature for subsequent H & E staining and immunohistochemical detection;

(7) Dewaxing: when H & E dyeing is carried out, dewaxing treatment is firstly carried out, the slices are placed in xylene for 30 minutes, then the other xylene is replaced for soaking for 10 minutes, and paraffin is completely removed;

(8) Rehydration: the paraffin sections are respectively placed in 100%, 95%, 80%, 70% and 50% ethanol for 5 minutes to rehydrate the tissues;

(9) H & E staining: placing the tissue slices subjected to rehydration treatment in a hematoxylin solution for staining for 15 minutes, washing for 30 minutes by running water, then washing by distilled water, treating for 6-8 seconds by hydrochloric acid alcohol, and then placing the tissue slices in an eosin solution for staining for 5 minutes;

(10) And (3) dehydrating: soaking the dyed slices in 50%, 70%, 80%, 95% and 100% ethanol for 5 minutes, respectively, then soaking in two dimethylbenzenes for 10 minutes, and finally sealing the slices with neutral gum;

(11) Observed under a microscope and photographed.

2.6 sequencing of rat feces 16s rDNA

2.6.1 fecal specimen DNA extraction

Fecal DNA was extracted using QIAamp DNA pool Mini Kit and run according to the instructions. The extracted genomic DNA was detected by electrophoresis on a 1% agarose gel.

2.6.2 fecal 1696 rDNAV3-4 region PCR amplification

The target fragment of the DNA of the intestinal flora is the V3-V4 region of 16S rDNA.

(1) 16S rDNA V3-V4 region primers are as follows:

(2) PCR amplification System:

(3) PCR amplification procedure:

a.1×(3minutes at 95℃)

b.29×(30seconds at 95℃；30seconds at 54℃；45seconds at 72℃)

c.10minutes at 72℃，10℃until halted by user

2.6.3 quantification of sequencing libraries and illumina MiSeq sequencing

The amplified product was subjected to gel cutting using AxyPrepDNA gel recovery kit (AXYGEN Co.) to recover the PCR product, and eluted with Tris-HCl; and (5) detecting by 2% agarose electrophoresis. Referring to the preliminary quantification result of electrophoresis, the PCR product was quantified using QuantiFluor ^TM The quantitative determination of ST blue fluorescence system (Promega corporation) followed by mixing in the corresponding proportions according to the sequencing requirements of each sample. Paired-end sequencing was finally performed using illumina MiSeq PE 300.

2.6.4 data processing and analysis

(1) Firstly, according to the overlap relation between PE reads, the reads in pairs are spliced into a sequence, meanwhile, quality control filtration is carried out on the similar and splicing effects of the reads, and samples are distinguished according to barcode and primer sequences at the head end and the tail end of the sequence to obtain an effective sequence. Removing the chimera sequence by adopting a UCHIME algorithm, and using the obtained effective sequence for downstream analysis. Data processing method and parameters: filtering bases with the tail mass value of less than 20 of reads, setting a window of 50bp, if the average mass value in the window is less than 20, cutting back-end bases from the window, and filtering reads with the mass value of less than 50bp after quality control; according to the overlap relation between PE reads, splicing the pairs of reads into a sequence, wherein the minimum overlap length is 10bp; the maximum mismatch ratio allowed by the overlap region of the splicing sequence is 0.2, and non-conforming sequences are screened; according to the barcode and the primer at the head and tail ends of the sequence, the samples are distinguished, the sequence direction is adjusted, the number of mismatch allowed by the barcode is 0, and the maximum primer mismatch number is 2.

(2) OUT clustering and annotation: the method comprises 5 steps of clustering OTU, selecting OTU representative sequences, annotating the OTU representative sequences, forming OTU table, and constructing tree development and evolution tree by the OTU representative sequences. Wherein OTU clustering is to perform self clustering according to 97% similarity through an effective sequence obtained through quality control; selecting an OTU representative sequence, and taking the sequence with the maximum number of reads in the obtained OTU cluster as the representative sequence; the OTU represents sequence annotation, which is to compare and annotate the representative sequence with an SILVA database to obtain annotation files of all layers; building a tree development evolutionary tree by the OTU representative sequence, and comparing the representative sequences to build the evolutionary tree for the analysis of the downstream evolution tree; an OTU table was formed and converted to an abundance annotation table for OTU using qiime software.

(3) Alpha analysis: in the step, after the obtained OTU table is utilized for leveling, comparison in a sample group is carried out, wherein the comparison comprises diversity index calculation, sparsity curve drawing, aroma curve drawing and rank curve drawing.

(4) Beta analysis: in the step, after the obtained OTU table is utilized for leveling, comparison among sample groups is carried out, wherein the comparison comprises PCA analysis, PCoA analysis and NMDS analysis

(5) Metastats analysis: analysis was performed by the metastats command of mothur, and differential abundance features of objective metagenomic samples were examined by comparison between the two groups. A P <0.05 is considered a significant difference.

2.7 rat feces/serum non-targeted metabolite UHPLC-TOF-LC-MS detection

2.7.1 sample pretreatment

(1) The feces/serum are thawed at room temperature, and 100 mu L of sample is absorbed into a 1.5mL EP tube by a pipette gun;

(2) Adding 300 mu L of methanol, and uniformly mixing for 30 seconds by vortex;

(3) Standing at-40 deg.C for 1 hr;

(4) Vortex and mix evenly for 30 seconds, and stand still for 0.5 hour at 4 ℃;

(5) Placing the mixture in a 4 ℃ centrifuge, and centrifuging the mixture for 15 minutes at 12000 rpm;

(6) Taking out all the supernatant liquid and placing the supernatant liquid in a centrifuge tube for 1 hour at minus 40 ℃;

(7) Placing the mixture in a 4 ℃ centrifuge, and centrifuging the mixture at 12000rpm for 15 minutes;

(8) Aspirate 200. Mu.L of supernatant and add 5. Mu.L of internal standard (140. Mu.g/mL, 2-chlorophenylalanine) and transfer to a sample vial for assay.

2.7.2LC-MS analysis

(1) An instrument analysis platform: LC-MS (AB SCIEX Triple TOF 6600+, nexera UHPLC LC-30A)

(2) A chromatographic column: (ACQUITY UPLC HSS T3,2.1mm 100mm 1.8 μm)

(3) The chromatographic separation conditions are as follows: the column temperature was 40 ℃; flow rate 0.3 mL/min;

mobile phase composition A: water +0.1% formic acid, B: acetonitrile +0.1% formic acid;

the sample size was 4. Mu.L, and the autosampler temperature was 4 ℃.

(4) The mobile phase gradient elution procedure is shown in table 1.

TABLE 1 procedure for elution of mobile phase

(5) Mass spectrum detection parameters:

the positive mode is as follows:

ion source (Ion source): ESI + ion source

Air Curtain Gas (Curtain Gas): 40arb

Ion spray voltage (ion spray voltage): 5500V

Ion source Temperature (Temperature): 550 deg.C

Ion source Gas (ion source Gas 1): 60arb

Ion source Gas (ion source Gas 2): 60arb

DP (declustering voltage): 80V CE (collision energy): 35V

A negative mode:

ion source (Ion source): ESI-ion source

Air Curtain Gas (Curtain Gas): 40arb

Ion spray voltage (ion spray voltage): -4500V

Ion source Temperature (Temperature): 550 deg.C

Ion source Gas (ion source Gas 1): 60arb

Ion source Gas (ion source Gas 2): 60arb

DP (declustering voltage): 80V CE (collision energy): -35V

2.7.3 data analysis

The method comprises the steps of firstly converting original data into an ABF format file by using AbfConverter.4.0.0 software, then carrying out peak extraction, peak comparison and peak filtration in MS-DIAL, supplementing missing peaks, identifying substances and the like, and finally standardizing the data into a two-dimensional data matrix in an Excel format, wherein the two-dimensional data matrix comprises information such as retention time, mass-to-charge ratio, observed quantity (samples), identified substances and peak intensity. The edited data matrix was imported into SIMCA-P14.0 (Umetrics AB, umea, sweden) software for multivariate statistical analysis.

2.8 human serum targeted metabolite UPLC-MS/MS detection

2.8.1 sample pretreatment

(1) To 80 μ L of the sample, 600 μ L of methanol acetone: water =65,

(2) Centrifuging for 10 min (10000rpm, 4 deg.C), collecting 500 μ L supernatant, volatilizing,

(3) Add 150 μ Ι of methanol-water =4 (v/v), vortex for 30 seconds, and sonicate in an ice water bath for 3 minutes to redissolve;

(4) Centrifuging for 10 min (10000rpm, 4 ℃), collecting 150 μ L supernatant, and placing into LC-MS sample injection vial;

(5) The quality control sample (QC) is prepared by mixing the extracting solutions of all samples in equal volume, and the volume of each QC is the same as that of the sample. Remarking: the samples were stored at-20 ℃ before loading on the machine. (the whole process ensures low temperature).

2.8.2 chromatographic Mass Spectrometry method

1. Chromatographic conditions

Sample injection amount: 5 μ L. Mobile phase: a (0.05% formic acid-water solution), B (acetonitrile: isopropanol 9.

Gradient Elution method (Gradient Elution Procedures): 0min A/B (45, 55, V/V), 0.5min A/B (45, 55, V/V), 2.5min A/B (0, 100, V/V), 4min A/B (0.

2. Conditions of Mass Spectrometry

Air curtain air: 35. collision-induced ionization (CAD) parameters: a medium. Positive ion spray voltage: 5500V; negative ion spray voltage: -4500V; temperature: 550 ℃; an ion source: gas1:55; gas2:55.

2.8.3 data analysis

Each MRM transition was automatically identified and integrated using default parameters in SCIEX OS-MQ software (SCIEX corporation, usa) and assisted with manual inspection. By performing overlapping display analysis on the total ion flow graphs of different quality control samples for mass spectrometry detection analysis and calculating the RSD value according to the data acquisition result (the RSD is less than or equal to 20), the repeatability of metabolite detection and the effect of technical repetition can be judged.

And manually correcting mass spectrum peaks detected by each metabolite in different samples according to the retention time and peak type information of the metabolite to ensure the accuracy of qualitative and quantitative analysis, wherein the peak area of each chromatographic peak represents the relative content of the corresponding metabolite, and finally obtaining the quantitative analysis integral result of all samples. And substituting the integrated peak area of the metabolite into a standard curve linear equation for calculation, and further substituting into a calculation formula for calculation to finally obtain absolute content data of each metabolite in the actual sample.

Metabolite content of sample (ng/mL) = N (C V1)/V2

The meaning of each letter in the formula:

c: carrying out concentration value (ng/mL) calculated by substituting peak area of metabolite in the sample into a standard curve;

v1: volume fixed (0.15 mL);

v2: sample volume (0.08 mL)

N: dilution factor (note: when undiluted, dilution factor is 1).

2.9 human fecal metagenome sequencing

2.9.1 Experimental procedure

1. DNA extraction: fecal DNA was extracted using the QIAamp DNA pool Mini Kit.

2. And (3) DNA quality inspection: electrophoresis on 1% agarose gel; the Qubit measures genomic DNA concentration.

3. DNA fragmentation: the DNA was broken into fragments of approximately 500 bp.

4. Library construction

(1) Repairing and connecting the tail end of the DNA fragment with A base; (2) connecting joints at two ends of the DNA fragment; (3) carrying out agarose gel electrophoresis for fragment screening; (4) PCR amplification and purification; (5) Agilent2100 detects library size, qPCR detects library molar concentration; (6) sodium hydroxide denaturation to generate single-stranded DNA fragments.

5. Cluster generation

(1) One end of the DNA fragment is complementary with the basic group of the primer and is fixed on the flowcell chip; (2) The other end is randomly complementary to another primer nearby and is also fixed to form a bridge; (3) PCR amplification to generate a DNA cluster; (4) linearization of the DNA clusters into single strands.

6. IlluminaHiSeq sequencing

(1) Adding DNA polymerase and 4 kinds of fluorescent labeled dNTPs into flowcell, and only doping single base in each circulation;

(2) Scanning the surface of the chip flowcell by laser, capturing a fluorescence signal, and reading the nucleotide species polymerized on each template sequence; (3) Chemically cutting the fluorescent group and the termination group, recovering the 3' end viscosity, and continuously doping a second round of single base; (4) And (4) counting the fluorescent signal results collected in each round in sequence to obtain the sequence of the template DNA fragment.

2.9.2 bioinformation analysis procedure

After the original sequence is subjected to quality control, on one hand, species compositions in a sample are analyzed by comparing a species database; and on the other hand, functional annotation is carried out through assembly and gene prediction on the basis of the assembly and the gene prediction.

2.9.3 data quality control

1. Raw data statistical analysis method

Each sample is not sequenced separately, but multiple samples are mixed together and sequenced in parallel. To allow for the discrimination of different samples, the sequence in each sample was introduced with an Index tag sequence (indicating the information from which the sample originated). Paired-end sequencing is carried out through an Illumina platform (Hiseq), then off-machine data of each sample is distinguished according to Index sequences, and extracted data are stored in a fastq format.

2. Data statistical analysis method

The 3' end of the original sequence is provided with an adaptor sequence and a few of low-quality data and impurity sequences, in addition, some samples have serious host pollution, and in order to improve the subsequent analysis quality and reliability, the original sequence needs to be subjected to adaptor removal, quality shearing, host DNA pollution removal, other pollution removal and the like. The specific analysis method comprises the following steps: removing reads containing Adaptor linker sequence pollution, removing reads containing N basic groups with the number more than or equal to 3, cutting the 3' end of the sequence, removing basic groups with the quality value less than 20, and filtering the reads with the length less than 60% of the original length after cutting; if the sample is from the host, the genomes of the host or the genomes of the species close to the host are found as much as possible, and reads polluted by the host are eliminated by aligning the genomes of the host by the SOAPaligner.

2.9.4 species annotation and differential species analysis

(1) Species annotation statistical analysis method

The CleanReads were aligned to a reference database constructed from known bacterial, fungal, viral and archaeal sequences in the NCBI database by SOAPaligner (version 2.21) with alignment parameters of-m 4-r2-m100-x1000[2], and then categorizing and abundance statistics were performed using reads on the alignment to construct taxonomy profiles at the corresponding taxonomic level.

(2) Species LEfSe difference analysis method

Linear discriminant analysis (LEfSe) is a software for finding high-dimensional biomarkers and revealing genomic features. Firstly, non-parametric factor Kruskal-Wallis sum-rank test is used to detect the characteristic of the difference with significant abundance, and a group with significant difference with the abundance is found, and then linear discriminant analysis is adopted to estimate the influence of the abundance of each component (species) on the difference effect, so as to find out the group or species which has significant difference influence on the sample division.

2.9.5 Gene set construction and analysis method

All the predicted genes were clustered (identity >95%, coverage > 90%) using CD-HIT (http:// www. Bioinformatics. Org/CD-HIT), and the remaining redundant genes were removed after selecting the longest gene sequence in each class, thereby constructing a non-redundant gene set for the relevant sample.

2.10 construction of L.reuteri-treated continuous dark rat intervention model

24 female SD rats of 6 weeks of age were randomly housed in 3 groups in an experimental environment of pathogen free (SPF) animals: control group, dark + l. The control group rats were treated with 12 hours of normal circadian rhythm 12 hours of light/dark (light on 30 in the morning, light off 30 in the afternoon) and given daily gavage with saline. The rats in the dark group were kept in a 24-hour constant dark environment for 8 weeks and were given gavage normal saline daily. The group of dark + L.reuteri is kept in dark for 8 weeks, and L.reuteri (10) is administered by gavage every day ¹⁰ CFU/mL,1 mL/d). Last 2 weeks of moldingVaginal smears record the estrous cycle.

3. Results of the experiment

(1) Lactobacillus reuteri improves PCOS-like phenotypes induced by biological clock disorders.

We find that the biological clock disorder caused by continuous darkness can cause abnormal expression of liver core rhythm genes of rats and PCOS-like symptoms such as androgen rise, glycolipid metabolism disorder, estrus cycle disorder, ovarian polycystic change and the like. While we administered lactobacillus reuteri intragastrics to rats (fig. 1A) while treating the rats for 8 weeks in darkness, we found that lactobacillus reuteri can improve liver lipid accumulation (fig. 1C-E), serum lipid metabolism disorder (fig. 1F), glycometabolism disorder (fig. 1G), ovarian polycystic change (fig. 1H) and estrus cycle disorder (fig. 1I) in the dark rats. Furthermore, lactobacillus reuteri significantly alleviated the higher SHBG levels in the serum of dark rats, but only tended to improve the serum LH/FSH ratio and testosterone levels (fig. 1J).

(2) Multiple panel analysis found intestinal flora, fecal metabolites and serum metabolites that play a role in the improved PCOS-like phenotype of lactobacillus reuteri.

A PCOS-like model of a continuous dark rat and a treatment model of a treatment dark rat treated by lactobacillus reuteri are utilized, and feces and peripheral serum are collected to perform feces 16s-rDNA sequencing, feces UHPLC-TOF-LC-MS and serum UHPLC-TOF-LC-MS sequencing. The results of PCA (Principal Component Analysis), PLS-DA (Partial Least Square disease purifying Analysis) and OPLS-DA (ortho PLS-DA) on fecal and serum metabolites showed significant differences in fecal and serum metabolites between the different treatments (FIG. 2).

We found that intestinal flora, including Lactobacillus, ruminobacillus-009, ruminobacillus-010, clostridium angularis-1 and g _ Family _ XIII _ AD3011_ group (FIG. 3A, 4A); fecal metabolites including MG (18/0, 0/0), ursodeoxycholic acid, 9-carbonyl-trans, cis-conjugated linoleic acid, glycyl, 3-methyladenine, L-carnitine, palmitic acid, chenodeoxycholic acid, azelaic acid, 13-methyltetradecanoic acid, succinic acid, N6-trimethyllysine, tetradecanoic acid, trigonelline, nicotinic acid, cis-eicosenoic acid, creatinine, pantothenic acid, ornithine, N-acetylaspartic acid, ferulic acid, murine cholic acid, oleic acid, 16-hydroxyhexadecanoic acid, adenine, maleic acid, pentadecanoic acid, γ -aminobutyric acid, 3-methylxanthine, cAMP, L-glutamine, 3-indoleacetic acid and N-acetyl-L-glutamic acid (fig. 3b, 4b); and serum metabolites, including allantoin, 13-methyltetradecanoic acid, thymine, dehydroabietic acid, gamma-linolenic acid, tetradecanoic acid, dUMP p, cortisol, cis-9-palmitoleic acid, decanoic acid, and citrulline (fig. 3c,4 c), play an important role in lactobacillus reuteri in ameliorating biological clockwork and in ameliorating PCOS-like phenotypes induced by biological clockwork.

(3) A multiomic combination analysis of intestinal flora, fecal metabolites and serum metabolites that play a role in the improved PCOS lipid metabolism disorder of lactobacillus reuteri.

Through combined omics analysis, we found that alterations in lactobacillus, ruminococcus-010, clostridium angustifolia-1 and g _ Family _ AD3011_ group, acting together, cause alterations in the fecal metabolites 13-methyltetradecanoic acid, nicotinic acid, glycyl, 9-carbonyl-trans, cis-conjugated linoleic acid, succinic acid, L-glutamine, azelaic acid, N-acetyl-L-glutamic acid, palmitic acid, cis-eicosenoic acid, MG (18.

(4) The content change of the target serum metabolite in the serum of the PCOS female and the diagnostic significance.

According to the animal experiment results, serum samples of 99 PCOS patients and 101 control normal women are collected, and the contents of cortisol, cis-9-palmitoleic acid, capric acid and 13-methyltetradecanoic acid in the serum are quantitatively detected by using an LC-MS (liquid chromatography-mass spectrometry) technology. We found that 13-methyltetradecanoic acid and PCOS in serum of patients with PCOS compared to control womenThe cis-9-palmitoleic acid concentration was significantly reduced (FIG. 6A-B), cortisol content was significantly increased (FIG. 6C), and decanoic acid levels were significantly reduced (FIG. 6D). Further performing Spearman analysis on metabolite content and clinical index, and suggesting that the group of different metabolites is related to BMI, TG, CHOL, HDL-C, AMH, LH/FSH, T ₀ There was a clear correlation between PRL, TSH and excellent embryo rate (fig. 6E).

We further judged the diagnostic effect of individual metabolites by the Area under the ROC curve (AUC) size, while the AUC-ROC of 3 combined metabolites of cortisol, cis-9-palmitoleic acid and 13-methyltetradecanoic acid was calculated to be 0.81 using logistic regression analysis, and 95% CI was 0.75-0.87 (FIG. 6F). The increased LH/FSH ratio is a more important auxiliary indicator in PCOS diagnosis, and if the three metabolites are used together with the LH/FSH ratio for PCOS diagnosis, the AUC-ROC of the LH/FSH ratio can be increased from 0.84 (95% CI. It is noteworthy that the use of 3 metabolites in combination with LH/FSH is more suitable for BMI<24 (AUC-ROC: 0.94, 95% CI. T is ₀ Elevated levels are one of the diagnostic conditions for PCOS. Combining 3 metabolites with T ₀ Application of, can be with T ₀ The AUC-ROC in the present queue rose from 0.92 (95% ci. In addition to LH/FSH and T ₀ The AUC-ROC for PCOS diagnosis using 3 metabolite combinations TG was also as high as 0.91 (95% CI: 0.86-0.96) (FIG. 6J), and the combination was more suitable for women with BMI ≧ 24 (AUC-ROC: 0.95, 95% CI. Therefore, the combined application of serum metabolites including 13-methyltetradecanoic acid, cortisol and cis-9-palmitoleic acid has high diagnostic value on PCOS, and the incidence of the PCOS may be related to biological disorders and has good treatment effect on L.reuteri.

(5) Metagenomic analysis suggests that there are various different intestinal bacteria in PCOS patients and their correlation with clinical indicators.

Intestinal feces of 14 PCOS patients and 10 control normal women were collected and analyzed by metagenomic sequencing and species LEfSe differential analysis to show that there was significant intestinal bacteria difference between the two groups of people (fig. 7). <xnotran> , PCOS (g __ Chrysosporum), (g __ Fusobacterium), (g __ Podoviridae), (g __ Shigella), (g __ Comamonas ), (g __ Parabacteroides), γ - (g __ Lambdalikevirus), (g __ Escherichia) (g __ Siphoviridae) , (g __ Klebsiella), (g __ Tannerella), (g __ Barnesiella) . </xnotran> In addition to this, the present invention is, escherichia (g _ Escherichia) and Zhi enriched in PCOS patients the Bacillus herbergii (g _ Shigella) was consistent with the animal modeling results described above.

Meanwhile, the intestinal bacteria screened by Metagenomic analysis are aggregated into a plurality of gene sets (MGS), and correlation analysis is carried out on the MGS and clinical indexes, so that obvious correlation exists. We found PCOS-enriched MGS and T ₀ AMH, LH, BMI are in positive correlation, and MGS and T enriched in a control group ₀ AMH, TSH were negatively correlated and positively correlated with fasting glucose (fig. 8).

The invention defines that the interaction network of the intestinal flora, the fecal metabolites and the serum metabolites plays a key role in improving the biological clock disorder and PCOS by the lactobacillus reuteri, and can be respectively and jointly used for diagnosis and treatment. The intestinal flora comprises Lactobacillus, ruminobacter-009, ruminobacter-010, clostridium stenosum-1, and g _ Family _ XIII _ AD3011_ group; fecal metabolites including MG (18/0; serum metabolites include allantoin, 13-methyltetradecanoic acid, thymine, dehydroabietic acid, gamma-linolenic acid, tetradecanoic acid, dUMP p, cortisol, cis-9-palmitoleic acid, decanoic acid, and citrulline.

While the preferred embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that the invention is not limited thereto, and that various changes and modifications may be made without departing from the spirit of the invention, and the scope of the appended claims is to be accorded the full range of equivalents.

Claims

1. Application of Lactobacillus reuteri in preparing medicine for treating polycystic ovary syndrome is provided.

2. The use of lactobacillus reuteri for the manufacture of a medicament for the treatment of polycystic ovarian syndrome as claimed in claim 1, wherein the polycystic ovarian syndrome is a polycystic ovarian syndrome induced by a disturbance of the organism's biological clock.

3. The use of lactobacillus reuteri for the manufacture of a medicament for the treatment of polycystic ovary syndrome according to claim 1, wherein said use is for the manufacture of a medicament for the amelioration of hepatic lipid accumulation, serum lipid metabolism, glucose metabolism, hyperandrogenism, ovarian polycystic change or estrus cycle disorders induced by disorders of the biological clock of the body.

4. The use of lactobacillus reuteri in the preparation of a medicament for the treatment of polycystic ovary syndrome according to claim 1, wherein the use is in the preparation of a medicament for improving intestinal flora, fecal metabolites and serum metabolites that play a role in the dyslipidaemia of polycystic ovary syndrome induced by disorders of the organism's biological clock.

5. The use of Lactobacillus reuteri for the manufacture of a medicament for the treatment of polycystic ovary syndrome according to claim 4, wherein the disorder of the lipid metabolism of polycystic ovary syndrome induced by the disorder of the biological clock of the body comprises the abnormality of serum triglycerides, free fatty acids, low density lipoproteins, cholesterol and high density lipoproteins.

6. The medicine for treating polycystic ovarian syndrome induced by organism biological clock disorder is characterized in that lactobacillus reuteri is used as an active ingredient.

7. The medicament for treating polycystic ovarian syndrome induced by the disturbance of the biological clock of a body according to claim 6, wherein the medicament for treating polycystic ovarian syndrome induced by the disturbance of the biological clock of a body is an oral preparation.